Marksans Pharma Ltd
NSE:MARKSANS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Marksans Pharma Ltd
Marksans Pharma Ltd
Net Income (Common)
Marksans Pharma Ltd
Net Income (Common) Peer Comparison
DRREDDY
CIPLA
SUNPHARMA
ZYDUSLIFE
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Marksans Pharma Ltd
NSE:MARKSANS
|
Net Income (Common)
₹3.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
33%
|
CAGR 10-Years
16%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Income (Common)
₹55.8B
|
CAGR 3-Years
42%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Income (Common)
₹41.2B
|
CAGR 3-Years
20%
|
CAGR 5-Years
22%
|
CAGR 10-Years
11%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Income (Common)
₹95.8B
|
CAGR 3-Years
49%
|
CAGR 5-Years
29%
|
CAGR 10-Years
12%
|
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Net Income (Common)
₹38.6B
|
CAGR 3-Years
22%
|
CAGR 5-Years
16%
|
CAGR 10-Years
17%
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Income (Common)
₹16.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
31%
|
CAGR 10-Years
10%
|
See Also
What is Marksans Pharma Ltd's Net Income (Common)?
Net Income (Common)
3.1B
INR
Based on the financial report for Mar 31, 2024, Marksans Pharma Ltd's Net Income (Common) amounts to 3.1B INR.
What is Marksans Pharma Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
16%
Over the last year, the Net Income (Common) growth was 18%. The average annual Net Income (Common) growth rates for Marksans Pharma Ltd have been 10% over the past three years , 33% over the past five years , and 16% over the past ten years .
You don't have any saved screeners yet
